Using a blood test to improve clot prevention in burn patients
Part of Blood & lymphatic clinical trials.
This study tests if using a blood test called anti-factor Xa helps doctors give the right amount of blood-thinning medicine to prevent clots in burn patients. It's for adults with moderate-to-large burns who need clot prevention while in the intensive care unit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years or older.
- Your burn must cover 20% to 59% of your body.
- You must arrive at the burn unit within 48 hours of the burn.
- You need a medicine to prevent blood clots because you can't move much or are having surgery.
- You cannot have a bleeding problem or be taking blood thinners before the burn.
- You don't have severe health problems like kidney failure, advanced cancer, or liver disease.
- Your weight must be between 100 and 330 pounds (45–150 kg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a blood thinner before placing a central line (a special IV) helps prevent clots in critically ill children. It could lower the risk of problems from the line.
This study looks at whether a blood test measuring a substance called anti-factor Xa activity can help predict dangerous blood clots in critically ill patients. If you join, researchers will follow you to see if the test results can prevent clots.
This study tests whether a blood thinner (LMWH) can help prevent dangerous blood clots in teens with a central line and infection or inflammation in the pediatric intensive care unit (PICU). It aims to find a safer, more personalized way to use preventive treatment.
This trial is testing a new way to give blood thinners to people who have been in a serious accident. The goal is to see if adjusting the dose based on your blood levels helps prevent dangerous blood clots.
This trial tests whether starting enoxaparin (a blood-thinner) within 24 hours after placing a specific type of central line can prevent dangerous clots. It may help reduce clot risk in people whose line is placed in the neck or thigh vein, while also tracking bleeding side effects.
This study looks at a prevention plan to reduce the risk of hospital-acquired blood clots. It may help people who are expected to stay in the hospital for several days but do not already have a clot.
Hear when a new Venous Thromboembolic Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.